Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06575374 · ClinicalTrials.gov registry record · Phase 2
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
A Phase 2 study of Cell Therapy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06575374: Recruiting Phase 2 study of Cell Therapy, sponsored by M.D. Anderson Cancer Center.
NCT06575374 is a Phase 2 study of Cell Therapy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants, below the 63-participant average among 3 other Cell Therapy trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06575374, a Phase 2 study of Cell Therapy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if a drug called Letermovir can help to prevent CMV reactivation.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Letermovir
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-12-12 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
What NCT06575374 shows while recruiting
NCT06575374 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 63-participant average among 3 other Cell Therapy trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Cell Therapy appearing as the primary indexed condition, and to 1 intervention - of which Letermovir is the first listed.
NCT06575374 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06575374 about?
NCT06575374 is a clinical study titled "Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell". The goal of this clinical research study is to learn if a drug called Letermovir can help to prevent CMV reactivation.
What is the current status of trial NCT06575374?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2024-12-12. Estimated completion is 2027-08-01.
What conditions does trial NCT06575374 study?
This clinical trial studies the following conditions: Cell Therapy.
What interventions are being tested in trial NCT06575374?
The interventions under investigation include: Letermovir (DRUG).
Who is sponsoring clinical trial NCT06575374?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06575374 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cell Therapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence
COMPLETED · Phase 2
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI